Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Status:
Withdrawn
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of lenalidomide when given together
with brentuximab vedotin in treating patients with T-cell lymphomas that have come back or do
not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere
with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as
lenalidomide, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
brentuximab vedotin and lenalidomide may work better in treating patients with T-cell
lymphomas.